Annexon’s GA drug misses on primary goal but win on visual acuity will be focus of planned late-stage trial

Kyle LaHucik

Senior Reporter

Annexon’s complement inhibitor didn’t prove better than sham at reducing lesion growth in a leading cause of blindness, but the biotech still plans to move …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Annexon’s GA drug misses on primary goal but win on visual acuity will be focus of planned late-stage trial

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Biotech VC firm outlines plans for $100M fund

FDA OKs the first-ever self-administered vaccine, for flu

The drug lobby's lawsuit against the IRA finds a sign of life after appeals court ruling

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Breaking down silos with a new quantitative approach to drug development

An­nex­on’s GA drug miss­es on pri­ma­ry goal but win on vi­su­al acu­ity will be fo­cus of planned late-stage tri­al

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Annexon’s GA drug misses on primary goal but win on visual acuity will be focus of planned late-stage trial